Back to discover
Drug
Oprozomib
Early clinical developmentClass26S proteasome inhibitor
38
Protein targets
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this drug.
Clinical trial2019-09-23Terminated · ClinicalTrials.gov
Clinical trial2019-08-12Terminated · ClinicalTrials.gov
Clinical trial2019-07-10Terminated · ClinicalTrials.gov
Clinical trial2019-06-25Terminated · ClinicalTrials.gov
Clinical trial2019-04-25Terminated · ClinicalTrials.gov
Clinical trial2015-09-01Completed · ClinicalTrials.gov
Clinical trial2015-03-01Withdrawn · ClinicalTrials.gov
Clinical trial2013-03-01Completed · ClinicalTrials.gov
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Canonical name
Oprozomib
RxNorm CUI
1678943
ChEMBL ID
CHEMBL2103884
UNII
MZ37792Y8J
Primary mechanism
26S proteasome inhibitor
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY8
registered trials across all phases
LATEST COMPLETION 2015
2
Completed
6
Discontinued
PHASE DISTRIBUTIONn = 8
Phase 13Phase 1 / 25
Recent completions
Trials that read out recently, adding to the completed evidence base.
References & data sources
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- ClinicalTrials.gov — clinical trials